



PHARMACEUTICAL 2020









PHARMACEUTICAL 2020



Karuna Therapeutics Inc. Rank 37 of 362



The relative strengths and weaknesses of Karuna Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karuna Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 308% points. The greatest weakness of Karuna Therapeutics Inc. is the variable Revenues, reducing the Economic Capital Ratio by 38% points.

The company's Economic Capital Ratio, given in the ranking table, is 126%, being 429% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	392,706
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,958
Liabilities, Non-Current	0
Other Assets	123
Other Compr. Net Income	5.0
Other Expenses	0
Other Liabilities	150
Other Net Income	1,448
Property and Equipment	195
Research and Development	24,536
Revenues	0
Selling, General and Administrative Expense	20,869

Output Variable	Value in 1000 USD
Assets	393,024
Liabilities	3,108
Expenses	45,405
Stockholders Equity	389,916
Net Income	-43,957
Comprehensive Net Income	-43,954
Economic Capital Ratio	126%